Regulatory

November 30, 2022

POP Biotechnologies’ SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.
November 30, 2022

POP Biotechnologies’ SNAP Vaccine Platform Enters Large Scale Clinical Trials for COVID-19

POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.
March 10, 2021
By JUSTIN WEISS March 3, 2021 | 10:18pm EST A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South […]
January 16, 2021

EuCorVac-19 gains regulatory approval for Phase I / II clinical studies

SNAP-based EuBiologics EuCorVac-19 gains regulatory approval for Phase I/II trials in Korea EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a […]